Literature DB >> 10895801

Gynecologic effects of tamoxifen: case reports and review of the literature.

R M Caputo1, L J Copeland.   

Abstract

The literature regarding the gynecologic effects of tamoxifen contains very little data on the vagina and lower urinary tract. The authors present two patients receiving tamoxifen who had gynecologic surgery complications that could be associated with tamoxifen use. Both patients had poor healing which improved when the tamoxifen was discontinued. Possible explanations are given for this observation based on what is known about this unusual drug. Owing to the success of tamoxifen in breast cancer patients, its use is currently being extended to include groups of healthy women at risk for the development of breast cancer. Because the number of women receiving tamoxifen may be increasing the authors include a review of its effects, with which all health care providers caring for women should be familiar.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 10895801     DOI: 10.1007/BF01907069

Source DB:  PubMed          Journal:  Int Urogynecol J Pelvic Floor Dysfunct


  72 in total

Review 1.  Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells.

Authors:  C L Arteaga; C K Osborne
Journal:  Cancer Treat Res       Date:  1991

2.  Oestrogen-like effect of tamoxifen on vaginal epithelium.

Authors:  E Ferrazzi; G Cartei; R Mattarazzo; M Fiorentino
Journal:  Br Med J       Date:  1977-05-21

3.  Endometrial polyps in postmenopausal patients receiving tamoxifen.

Authors:  M A Nuovo; G J Nuovo; R M McCaffrey; R U Levine; B Barron; B Winkler
Journal:  Int J Gynecol Pathol       Date:  1989       Impact factor: 2.762

4.  Six-year results of a controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer.

Authors:  A J Wilson; M Baum; D M Brinkley; J A Dossett; K McPherson; J S Patterson; R D Rubens; F G Smiddy; B A Stoll; D Richards
Journal:  World J Surg       Date:  1985-10       Impact factor: 3.352

5.  A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.

Authors:  A Lipton; H A Harvey; R J Santen; A Boucher; D White; A Bernath; R Dixon; G Richards; A Shafik
Journal:  Cancer       Date:  1982-12-01       Impact factor: 6.860

6.  Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh.

Authors: 
Journal:  Lancet       Date:  1987-07-25       Impact factor: 79.321

7.  Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

Authors:  B Fisher; J P Costantino; C K Redmond; E R Fisher; D L Wickerham; W M Cronin
Journal:  J Natl Cancer Inst       Date:  1994-04-06       Impact factor: 13.506

8.  Antitumor activity of clomiphene analogs in vitro: relationship to affinity for the estrogen receptor and another high affinity antiestrogen-binding site.

Authors:  L C Murphy; R L Sutherland
Journal:  J Clin Endocrinol Metab       Date:  1983-08       Impact factor: 5.958

9.  Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen.

Authors:  S Rössner; A Wallgren
Journal:  Atherosclerosis       Date:  1984-09       Impact factor: 5.162

10.  Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.